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ABSTRACT
Objectives: Control of the tuberculosis (TB) epidemic
is a global health priority and one that is likely to be
achieved only through vaccination. The critical overlap
with the HIV epidemic requires any effective TB vaccine
regimen to be safe in individuals who are infected with
HIV. The objectives of this clinical trial were to evaluate
the safety and immunogenicity of a leading candidate
TB vaccine, MVA85A, in healthy, HIV-infected adults.
Design: This was an open-label Phase I trial,
performed in 20 healthy HIV-infected, antiretroviral-
naı ¨ve subjects. Two different doses of MVA85A were
each evaluated as a single immunisation in 10
subjects, with 24 weeks of follow-up. The safety of
MVA85A was assessed by clinical and laboratory
markers, including regular CD4 counts and HIV RNA
load measurements. Vaccine immunogenicity was
assessed by ex vivo interferon g (IFN-g) ELISpot
assays and ﬂow-cytometric analysis.
Results: MVA85A was safe in subjects with HIV
infection, with an adverse-event proﬁle comparable
with historical data from previous trials in HIV-
uninfected subjects. There were no clinically signiﬁcant
vaccine-related changes in CD4 count or HIV RNA load
in any subjects, and no evidence from qPCR analyses
to indicate that MVA85A vaccination leads to
widespread preferential infection of vaccine-induced
CD4 T cell populations. Both doses of MVA85A
induced an antigen-speciﬁc IFN-g response that was
durable for 24 weeks, although of a lesser magnitude
compared with historical data from HIV-uninfected
subjects. The functional quality of the vaccine-induced
T cell response in HIV-infected subjects was
remarkably comparable with that observed in healthy
HIV-uninfected controls, but less durable.
Conclusion: MVA85A is safe and immunogenic in
healthy adults infected with HIV. Further safety and
efﬁcacy evaluation of this candidate vaccine in TB- and
HIV-endemic areas is merited.
INTRODUCTION
Tuberculosis (TB) and HIV are inextricably
linked. At the end of 2007, approximately
33.2 million persons were living with HIV-1
infection, an estimated one-third of whom
were co-infected with Mycobacterium tubercu-
losis.
1 TB is the cause of death for up to half
of all AIDS patients,
2 and the increasing
incidence of drug-resistant strains of M
tuberculosis poses a signiﬁcant threat to
a susceptible HIV-infected population.
3
Mycobacterium bovis BCG fails to protect
consistently against the adult pulmonary
form of TB, while providing reliable protec-
tion against disseminated infection in
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ARTICLE SUMMARY
Article focus
- HIV infection increases susceptibility to TB, and
globally, TB is the cause of death in up to half of
AIDS deaths.
- There is an urgent need for a safe and effective
TB vaccine in HIV-infected people.
Key messages
- MVA85A, a leading candidate TB vaccine, is safe
and well tolerated in HIV-infected people and
does not induce changes in either CD4 count or
HIV RNA load.
- MVA85A is immunogenic in HIV-infected people,
and induces a similar immune proﬁle to that seen
in HIV-uninfected people, but the immunoge-
nicity is less durable in HIV-infected people.
Strengths and limitations of this study
- This is a Phase I study with 20 subjects, and
further studies are needed in TB endemic
countries in this important target population.
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4 An improved vaccine strategy is thus essen-
tial for global control of this disease.
5 MVA85A (modi-
ﬁed vaccinia virus Ankara expressing antigen 85A) is
a leading candidate TB vaccine, designed to enhance the
effect of BCG; it is safe and highly immunogenic in
healthy BCG-naı ¨ve and BCG-vaccinated subjects, and in
subjects latently infected with M tuberculosis in the UK
and Africa.
6e11
It is essential that any new TB vaccine is safe in an HIV-
infected population. Subunit vaccines are an ideal choice
for an immunocompromised population in which the
safety of replicating whole organism vaccines may be
a concern. Although MVA is a live viral vaccine vector, it
cannot replicate in human cells.
12 13 There are now safety
data from a number of clinical trials with recombinant
MVAs in HIV-infected subjects, which demonstrate no
sustained effect on either HIV load or CD4 count.
14e16
Most of these studies assessed immune-reconstituted
HIV-infected individuals on antiretroviral therapy (ARV);
however, some ARV-naı ¨ve subjects with more advanced
HIV infection have also been vaccinated with a recombi-
nant MVA, with no signiﬁcant rise in HIV load or fall in
CD4 count over a 4-week follow-up period.
17 Preclinical
studies in severely immunosuppressed macaques have
also documented safety in this model.
18 To date, MVA85A
has been administered to more than 1000 individuals
with no vaccine-related serious adverse events
68 e11
(McShane, unpublished data).
Here we present the ﬁrst clinical trial of a subunit TB
vaccine in an HIV-infected population. The primary
endpoint was to evaluate the safety of two doses of
MVA85A in healthy HIV-infected subjects in the UK, and
the secondary endpoint was to evaluate the immunoge-
nicity of this vaccine regimen.
METHODS
Trial design and participants
The protocol for this multisite study was approved by the
Medicines and Healthcare Products Regulatory Agency
(MHRA), and ethical approval was obtained from the
Gene Therapy Advisory Committee (GTAC). Participants
were recruited from the Genitourinary Medicine (GUM)
departments at the Oxford Radcliffe Hospitals NHS
Trust, University Hospitals Birmingham NHS Founda-
tion Trust (Selly Oak Hospital), Great Western Hospitals
NHS Foundation Trust and Imperial College Healthcare
NHS Trust, London.
Potentially eligible subjects were referred to the
clinical trial team. Vaccination visits took place in
Oxford; screening and follow-up visits took place at local
NHS Trust sites. Written informed consent was obtained
from all subjects prior to enrolment in the trial, and the
referring HIV physicians were notiﬁed.
Eligibility required participants to be generally
healthy, aged 18e55 years, with a normal chest radio-
graph and no clinical or radiological evidence of TB
disease, a current CD4 count (measured at screening) of
at least 350310
6/l, a nadir CD4 count of not less than
300310
6/l and an HIV RNA load at screening of less
than 100000 copies/ml. All subjects were diagnosed as
having HIV infection at least 6 months before screening
and had not received any ARVs within the preceding
6 months (full inclusion/exclusion criteria; table 1). In
all cases, testing for latent M tuberculosis infection (LTBI)
was conducted at screening using an in-house ex-vivo
interferon g (IFN-g) ELISpot assay for ESAT6 and
CFP10 peptides. Subjects found to be latently infected
were referred back to their consultants for possible
treatment at the end of the trial.
The trial was registered on a clinical trials database:
ClinicalTrials.gov ID NCT00395720.
Vaccine
Clinical grade MVA was produced under Good
Manufacturing Practice standard by IDT Biologika
GmbH (Dessau-Rosslau, Germany).
Procedures
The ﬁrst group of 10 subjects were vaccinated intrader-
mally with MVA85A at a dose of 5310
7 plaque-forming
units (pfu); the second group of 10 subjects were
subsequently vaccinated with a dose of 1310
8 pfu
MVA85A. Subjects were sequentially allocated ﬁrst to the
low-dose group and then, once safety had been
demonstrated, to the high-dose group. A diary card was
completed by all subjects recording local and systemic
adverse events and body temperature for days 1 to 7
postvaccination. All subjects were followed up regularly
for 12 months, and blood samples were taken at each
time-point for CD4 count, HIV RNA load measurement
and cellular immunological assays. CD4 count and HIV
RNA load results were communicated to the patient’s
HIV physician at regular intervals. Routine haematology
and biochemistry assays were performed at weeks 1 and
12 after vaccination. All subjects attended their usual
NHS follow-up appointments and received routine
clinical care throughout the trial.
Immunological assays
Ex vivo IFN-g ELISpot assays were performed at
screening and at weeks 1, 2, 4, 12 and 24 postvaccination
using fresh peripheral blood mononuclear cells
(PBMCs), as described previously.
10 A single pool of 15-
mer peptides spanning the Ag85A protein (66, over-
lapping by 10 amino acids, 2 mg/ml ﬁnal concentration
of each peptide in each well) and seven pools of non-
overlapping 9e10 Ag85A peptides (ﬁnal concentration
of 10 mg/ml in each well) were used to stimulate for the
IFN-g ELISpot assays. For the seven peptide pool wells,
the results were summed across all peptide pools for
each time-point. This potentially resulted in duplicate
counting of T cells that responded to any of the 10mer
overlap regions, since any 10mer occurred in two pools
with adjacent peptides, but allows direct comparison
with immunogenicity data from previous trials.
Intracellular cytokine staining of PBMCs was
performed as described previously.
19 Brieﬂy, cells were
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dye ViViD (Molecular Probes, Invitrogen, Eugene,
Oregon) and then surface-stained with monoclonal
antibodies against CD4, CD14, CD19, CD27, CD45RO,
CD57 and CCR5. After washing, cells were permeabilised
(Cytoﬁx/cytoperm kit; BD Pharmingen, San Diego,
California) and stained intracellularly for CD3, CD8,
IFN-g,T N F - a, IL-2 and MIP-1b.N a ı ¨ve CD4 memory cells
were identiﬁed as CD45RO-CD27+CD57+; memory CD4
T cell as CD45RO+CD276CD576. CD4 T cells
producing two or more cytokines (IFN-g, IL-2 or TNF-a)
following stimulation with Ag85A peptides were sorted
to greater than 98% purity using a modifed FACSAria
ﬂow cytometer (BD Biosciences, San Jose, California);
CMV-speciﬁc CD4 T cells, deﬁned similarly, and bulk
resting memory CD4 T cells were sorted simultaneously.
Cytokine production and the expression of surface
markers were analysed using FlowJo Tree Star Inc version
8.7, Pestle version 1.5 and SPICE version 4.1 (both from
Mario Roederer, Vaccine Research Center, National
Institute of Allergy and Infectious Diseases, National
Institutes of Health).
Table 1 Full inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
< Healthy adults aged 18e55 years
< Willingness to allow the investigators to discuss
the volunteer’s medical history with the volunteer’s
HIV lead physician (and GP, if appropriate)
< HIV antibody positive; diagnosed at least 6 months
previously
< CD4 count >350; nadir CD4 not <300
< HIV viral load not > 100000 copies/ml
< Written informed consent
< Any clinically signiﬁcant abnormal ﬁnding on screening
biochemistry or haematology blood tests or on urinalysis
< Any antiretroviral therapy within the past 6 months
< Any AIDS-deﬁning illness
< Chest x ray showing tuberculosis or evidence of other
active infection
< Prior receipt of a recombinant MVA or Fowlpox vaccine
< Use of any investigational or non-registered drug, live
vaccine or medical device other than the study vaccine
within 30 days preceding dosing of study vaccine, or
planned use during the study period
< Administration of chronic (deﬁned as more than 14 days)
immunosuppressive drugs or other immune modifying drugs
within 6 months of vaccination (for corticosteroids, this will
mean prednisolone, or equivalent, $0.5 mg/kg/day; inhaled
and topical steroids are allowed)
< History of allergic disease or reactions likely to be
exacerbated by any component of the vaccinedfor
example, egg products
< Presence of any underlying disease that compromises the
diagnosis and evaluation of response to the vaccine
(including evidence of cardiovascular disease, history of
cancer (except basal cell carcinoma of the skin and cervical
carcinoma in situ), history of insulin requiring diabetes
mellitus, any ongoing chronic illness requiring ongoing
specialist supervision (eg, gastrointestinal), and chronic or
active neurological disease)
< History of $2 hospitalisations for invasive bacterial
infections (pneumonia, meningitis)
< Suspected or known current drug and/or alcohol abuse
(as deﬁned by an alcohol intake of >42 units a week)
< Seropositive for hepatitis B surface antigen and/or hepatitis
C antibodies
< Evidence of serious psychiatric condition
< Any other ongoing chronic illness requiring hospital
specialist supervision
< Administration of immunoglobulins and/or any blood
products within the 3 months preceding the planned
administration of the vaccine candidate
< Pregnant/lactating female and any female who is willing
or intends to become pregnant during the study
< Any history of anaphylaxis in reaction to vaccination
< Principal investigator assessment of lack of willingness to participate
and comply with all requirements of the protocol, or identiﬁcation
of any factor felt to signiﬁcantly increase the participant’s
risk of suffering an adverse outcome
Subjects were required to meet all of the inclusion criteria to participate in the study.
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mine the proportion of HIV-infected Ag85A-speciﬁc
CD4 T cells; resting memory CD4 T cells (non-Ag85A-
speciﬁc) and CMV-speciﬁc CD4 T cells were used as
intraindividual controls. HIV-1 gag proviral DNA within
sorted CD4 Tcell populations was quantiﬁed by qPCR, as
described previously.
20 qPCR was performed simulta-
neously for albumin gene copy number in all sorted CD4
T cell populations to quantify cell number in each
reaction. HIV-1 gag primers for qPCR: the Gag clade B
primer position and sequence were 795gagB-F: ggtgcga-
gagcgtcagtattaag, 911gagB-R: agctccctgcttgcccata, and
the probe was 841gagB-P: FAM-aaaattcggttaaggccagggg-
gaagaa-QSY7 (MegaBases). The Gag clade C primer
position and sequence were 689gagC-F: ggggaagtgaYa-
tagcagga, 841gagC-R: ggYccttgtYttatgtccaa, and the
probe was 710gagC-P: ctactagtaVccttcaRgaacaRata
Rcatggatga. The albumin primer sequences were Alb-F:
tgcatgagaaaacgccagtaa, Alb-R: atggtcgcctgttcaccaa,
and the probe: Alb-P: FAM-tgacagagtcaccaaatgctgca-
cagaa-QSY7. The degenerate HIV gag clade A/G primer
position and sequence were 783gagA/G-F: 59-gagaga-
gatgggtgcgagagcgtc-39 (GAGAGAGATGGGTGCGAGAG
CGTC), 895gagA/G-R: 59-ctttccagctccctgcttgccca-39, and
the probe was 844gagA/G-P: 59-attcggttaaggccagggg-
gaaagaaaaaat-39.
CD4 T cells from 12 subjects (4/10 in the low-dose
group and 8/10 in the high-dose group) were analysed
for HIV gag content; low sort yields (less than 250
antigen-speciﬁc CD4 T cells) prevented similar analyses
in the remaining eight subjects.
Serum levels of MIP-1a, MIP-1b, RANTES, TNF-a and
IL-2 were measured prevaccination and at weeks 1, 2 and
24 postvaccination using FlowCytomix simplex kits
(Bender MedSystems, Vienna). Serum was thawed and
plated out in duplicate in round-bottom 96-well plates.
Samples were used neat for MIP-1a, MIP-1b, TNF-a and
IL-2, and diluted 1/10 for RANTES. Standards
(provided) were reconstituted as speciﬁed, and 1/3 serial
dilutions plated in duplicate. Bead and biotin-conjugate
cocktails were added to each well in 25 ml and 50 ml
volumes, respectively, and incubated for 2 h in the dark
at room temperature. Samples were then washed twice in
100 ml assay buffer. Streptavidin-PE (50 ml) and assay
buffer (100 ml) were added, and plates were incubated
for 1 h in the dark at room temperature. Samples were
then washed again and transferred to cluster tubes in 4%
paraformaldehyde in PBS (400 ml) and acquired using an
LSRII ﬂow cytometer (BD Biosciences) set up with the
beads provided and the highest concentration standard;
the stopping gate was set so that at least 300 events were
collected for each sample. Data were analysed using
FlowCytomixPro software (Bender MedSystems).
Statistical analysis
Continuous outcomes were presented as a median
(range) for each group. The median difference was
calculated to assess the difference between two groups,
and the corresponding 95% CI was computed using the
robust method proposed by Newson.
21 The overall
magnitude of vaccine-induced CD4 Tcell responses over
the 24 weeks was summarised using the area under the
curve (AUC) for each dose group. Peak (1 week) and
plateau (24 weeks) CD4 T cell responses were compared
with those at baseline (prevaccination) using the
Wilcoxon signed rank test, Stata Statistical Software,
Release 9.0. 2005. The ManneWhitney U test was used to
compare between the vaccine groups. Comparisons
between speciﬁc time points in this trial and previously
published trials of MVA85A,
62 2and between low- and
high-dose groups were conducted using the
ManneWhitney U test (Stata).
Non-parametric Spearman rank analyses were used to
correlate immune assays and CD4/HIV RNA load with
CD4 T cell responses.
RESULTS
Thirty-ﬁve individuals attended for screening between
October 2006 and June 2009; 20 subjects were enrolled
(supplement ﬁgure 1, ﬂow chart). The demographics of
the 20 participants are shown in table 2 and were
comparable across the two groups.
Safety of MVA85A in HIV-infected subjects
Local reactions related to the MVA vaccine occur during
the ﬁrst week after vaccination and have been reported
previously.
6 71 0The local adverse event (AE) proﬁle
recorded in the diary cards of the HIV-infected subjects
in this study was comparable with that observed in HIV-
uninfected subjects
671 0(Pathan et al, unpublished
data), although pruritus appeared slightly higher in the
HIV-infected group (table 3a). There were no severe
local reactions, and most local AEs were mild.
Table 2 Subject demographics: comparison of low and
high dose vaccination groups
Demographics and
screening results
Low dose High dose
5310
7 pfu 1310
8 pfu
Sex
Male 9 (90%) 8 (80%)
Female 1 (10%) 2 (20%)
Median age (range) 35.8 (21e52) 35.1 (27e46)
Continent of birth
Africa 4 (40%) 4 (40%)
Asia 0 1 (10%)
Europe 4 (40%) 5 (40%)
North America 1 (10%) 0
South America 1 (10%) 0
BCG
Deﬁnite 7 (70%) 10 (100%)
Uncertain 3 (30%) 0 (0%)
Latent infection
(ESAT-6/CFP-10 +)
2 (20%) 3 (30%)
Median CD4 count
(range)
570
(430e1200)
625
(410e840)
Median HIV RNA
load (range)
6069
(39e41890)
14805
(49e71090)
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a single episode of fever greater than 37.58C (docu-
mented at 38.18C). All other subjective systemic symp-
toms occurred with similar frequencies in the low-dose
and high-dose groups (table 3b). There was one
moderate systemic AE, and all others were mild.
The prevaccination CD4 counts and HIV RNA loads
for all 20 subjects over a time period of 1e6 years before
enrolment are shown in ﬁgure 1. These longitudinal
data illustrate the levels of natural ﬂuctuation that occur
over time and represent important baseline measure-
ments for the interpretation of these parameters post-
vaccination, also shown in ﬁgure 1, in the absence of an
unvaccinated control group. No clinically signiﬁcant
changes in CD4 counts or HIV RNA load were seen
postvaccination.
A major concern with respect to the vaccination of
HIV-infected individuals is the possibility that
responding antigen-speciﬁc CD4 T cells will act as
preferential targets for HIV infection as a function of
their activated status, thereby enhancing the propa-
gation of HIV and accelerating disease progression. In
this study, however, there was no evidence for prefer-
ential HIV infection of Ag85A-speciﬁc CD4 Tcells. The
median number of CD4 Tcells in Ag85A-speciﬁc qPCR
reactions was 73 (95% CI 15 to 130 CD4 T cells).
Where possible, multiple time-points throughout the
vaccination course for each subject were analysed, to
determine the proportion of Ag85A-speciﬁc CD4 T
cells that were infected with HIV. Of 29 Ag85A-speciﬁc
CD4 T cell samples in total (11 subjects), only one
subject showed a positive signal for HIV gag DNA by
qPCR at two different postvaccination timepoints
(weeks 2 and 8 postvaccination; data not shown). In
the 11 subjects tested, resting HIV-speciﬁc and CMV-
speciﬁc memory cell populations showed a positive
signal in all assays (data not shown). In addition,
vaccination had no effect on levels of MIP-1a,M I P - 1 b,
RANTES, TNF-a and IL-2 in unstimulated serum (data
not shown).
Immunogenicity of MVA85A in HIV-infected subjects
MVA85A induced signiﬁcant antigen-speciﬁc T cell
responses as measured by the IFN-g ELISpot assay
(ﬁgure 2AeD, table 4). In the low-dose group, the
frequency of IFN-g-secreting T cells responding to the
single 85A peptide pool at week 1 postvaccination
increased by a median of 393 spot forming cells (sfc)/
million compared with prevaccination baseline
measured on the day of screening (p¼0.009); there,
a signiﬁcant increase remained until 24 weeks post-
vaccination (p¼0.032). In the high-dose group,
a median increase of 502 sfc/million was apparent at
week 1 postvaccination (p¼0.005); again, this response
was maintained until 24 weeks (p¼0.048). In both
groups, T cell responses to the summed 85A peptide
pools followed a similar pattern with a signiﬁcant
increase above baseline at week 1 (738 and 1730 sfc/
million for low- and high-dose groups, respectively),
although, the week 24 response was only maintained
signiﬁcantly above baseline in the high-dose group (low
dose p¼0.17; high dose p¼0.007). There were no
signiﬁcant differences in the overall magnitude (ie,
AUC) of the IFN-g response between the low- and high-
dose groups across the follow-up period (p¼0.29 and
p¼0.68 for summed and single peptide pools,
Table 3 Local and systemic adverse events: Comparison of low- and high-dose vaccination groups with dose-matched
HIV-uninfected subjects from previous trials of MVA85A
671 0(Pathan et al, unpublished data)
HIV-infected HIV-negative
Dose 5310
7 pfu 1310
8 pfu 5310
7 pfu 1310
8 pfu
No of subjects n[10 n[10 n[43 n[12
(a) Local adverse events
Redness 10 (100%) 10 (100%) 42 (98%) 12 (100%)
Pruritus 10 (100%) 9 (90%) 22 (51%) 8 (67%)
Pain 8 (80%) 7 (70%) 36 (84%) 12 (100%)
Induration 10 (100%) 10 (100%) 42 (98%) 12 (100%)
(b) Systemic adverse events
Measured fever 1 (10%) 0 (0%) 3 (7%) 5 (42%)
Subjective fever 3 (30%) 2 (20%) 17 (40%) 9 (75%)
Arthralgia 2 (20%) 3 (30%) 6 (14%) 7 (58%)
Headache 6 (60%) 4 (40%) 21 (49%) 10 (83%)
Myalgia 1 (10%) 2 (20%) 18 (42%) 9 (75%)
Nausea 1 (10%) 0 (0%) 4 (9%) 4 (33%)
Vasovagal syncope 0 (0%) 1 (10%) 0 (0%) 0 (0%)
Axillary lymphadenopathy 1 (10%) 0 (0%) 2 (5%) 2 (17%)
Change in haematology/biochemistry 0 (0%) 0 (0%) 0 (0%) 0 (0%)
There were signiﬁcantly fewer systemic AEs per person (and a lower frequency of systemic AEs overall) in the 10 HIV-infected subjects
receiving high-dose MVA85A compared with HIV-uninfected subjects receiving the same dose of vaccine (p¼0.026, data not shown and Pathan
et al, unpublished).
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rate was higher in the high-dose group with no observed
non-responders (ie, those subjects with no measurable
vaccine induced immune response) compared with 1e2
non-responders (depending on antigen) in the low-dose
group. Overall, the kinetics of the Ag85A-speciﬁc T cell
responses were very similar to those previously reported
in similar studies of HIV-uninfected subjects.
6e11
Ag85A-speciﬁc T cell responses in the low-dose group
were signiﬁcantly lower compared with those observed in
previously published studies of HIV-uninfected subjects
(AUC analysis, p¼0.02; table 5).
62 2This difference was
not signiﬁcant at week 1 (MWU analysis, p¼0.12), which
represents the peak response, but was signiﬁcant at week
24 postvaccination (MWU analysis, p¼0.004; table 5,
ﬁgure 2EeG). There were no signiﬁcant differences in
baseline (prevaccination) responses between the HIV-
infected and HIV-uninfected groups (MWU analysis,
p¼0.85; ﬁgure 2E). Similarly, HIV-infected subjects in
the high-dose group exhibited signiﬁcantly lower
responses compared with HIV-uninfected subjects who
received the same dose of MVA85A (AUC analysis,
p¼0.0001; week 1 and week 24 MWU analysis, p¼0.0001;
table 5, ﬁgure 3EeG). Again, baseline responses were
comparable (p¼0.24) (ﬁgure 2E).
There was no signiﬁcant correlation between the CD4
count at screening and the peak summed 85A peptide
pool response (R¼0.04, p¼0.09), nor between HIV RNA
load at screening and the peak immune response
(R¼ 0.04, p¼0.08). There was a strong negative corre-
lation between viral load at screening and the plateau
immune response at week 24 (R¼ 0.8, p¼0.002).
Figure 1 (AeD) Comparison of
pre- and postvaccination CD4
counts: longitudinal CD4 counts of
subjects in the low-dose
(5310
7 pfu MVA85A) group
pre-vaccination, (A); and high-
dose (1310
8 pfu MVA85A) group
(C) prevaccination. Longitudinal
CD4 counts postvaccination (up to
24 weeks) in the low-dose (B) and
high-dose (D) groups. The x-axis
for the prevaccination data is not
standardised for time but varies
from 1 to 6 years, depending on
the individual subject. (EeH)
Comparison of pre- and
postvaccination HIV RNA loads:
longitudinal HIV RNA loads of
subjects in the low-dose (E) and
high-dose (G) groups
prevaccination. Longitudinal HIV
RNA loads postvaccination (up to
24 weeks) in the low-dose (F) and
high-dose (H) groups. Anonymous
number codes (001e036) are
shown in the key. The x-axis for
the prevaccination data is not
standardised for time but varies
from 1 to 6 years depending on
the individual subject.
AB
CD
EF
GH
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were no signiﬁcant postvaccination changes in the
magnitude of ESAT-6/CFP10 responses in these subjects
(data not shown).
Ag85A-speciﬁc cytokine/chemokine production by CD4
Tcells prior to MVA85A vaccination was undetectable and
increased signiﬁcantly postvaccination (ﬁgure 3A). One
week following MVA85A vaccination, more than 40% of
Ag85A-speciﬁc CD4 T cells produced IFN-g, IL-2, MIP-1b
and TNF-a simultaneously (p<0.01); this remained
signiﬁcant at week 2 (p<0.05). By week 8 postvaccination,
60% of Ag85A-speciﬁc CD4 T cells were still producing
IFN-g, IL-2 and TNF-a simultaneously; production of IL-2
and IFN-g was maintained until 24 weeks. Production of
MIP-1b was not detected beyond week 2 postvaccination
(ﬁgures 3A, 4A). In the ﬁrst 2 weeks postvaccination,
Ag85A-speciﬁc CD4 T cells exhibited similar functional
proﬁles in the HIV-infected groups, both low-dose and
Figure 2 (AeD) IFN-g ELISpot
responses in the low-dose and
high-dose groups. Longitudinal
responses to the single 85A
peptide pool are shown for the
low-dose (5310
7 pfu MVA85A)
group, (A) and high-dose
(1310
8 pfu MVA85A) group (B).
Longitudinal responses to the
summed 85A peptide pools are
shown for the low-dose (C) and
high-dose (D) groups. Horizontal
bars represent the median
response. Comparison of IFN-g
ELISpot responses in HIV-
infected and HIV-uninfected
subjects (EeG). Responses to
summed 85A peptide pools for
low-dose and high-dose vaccine
regimes at screening (E); week 1
postvaccination (F) and week 24
postvaccination (G). Subjects with
LTBI are denoted by grey
symbols. Statistically signiﬁcant
differences in the responses
between HIV-infected and
HIV-uninfected subjects were
assessed using the
ManneWhitney U test. *p<0.05,
**p<0.01, ***p<0.001. Horizontal
bars represent the median
response
671 0(Pathan et al,
unpublished data).
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group; in all cases, the responses were dominated by four
functionally distinct subsets (ﬁgure 3B,C). IFN-g
production measured by ICS correlated closely with IFN-g
secretion observed in the ELISpot assay (R¼0.75,
p<0.0001, n¼45; data not shown).
Surface expression of the HIV M-tropic co-receptor
CCR5 was monitored throughout the course of vaccina-
tion (ﬁgure 4). At week 1 postvaccination, the MFI for
CCR5 was highest in the activated Ag85A-speciﬁc CD4 T
cells and lowest in the naı ¨ve CD4 T cell subsets. Using
the integrated MFI (iMFI) function calculated using
both MFI and cell frequencies, expression of CCR5 was
highest in the much larger memory CD4 T cell pool
(ﬁgure 4D). No signiﬁcant increase in CCR5 expression
was detected in either the memory (ﬁgure 4E) or the
total (ﬁgure 4F) CD4 T cell populations as a result of
MVA85A vaccination.
DISCUSSION
This is the ﬁrst Phase I trial of a subunit vectored TB
vaccine in HIV-infected individuals. The two main ﬁnd-
ings of this study are that MVA85A is safe in healthy
subjects infected with HIV (a proportion of whom are
co-infected with M tuberculosis), and that MVA85A is
immunogenic in this population, albeit at a lower level
than in HIV-uninfected subjects. As a result of these
promising ﬁndings, similar studies in South Africa
Table 4 Ex vivo IFN-g ELISpot statistics (1): comparison of screening, week 1 and week 24 responses within low- and high-
dose groups, for both summed and single pooled peptides, using the Wilcoxon signed rank test
Dose
Screening
(n[10)
Week 1
(n[10)
Week 24
(n[10)
Summed pooled peptidesdwithin-dose changes from screening to peak and plateau
Low
Median (range) 10 (3e20) 738 (109e4398) 20 (0e237), n¼9
Median difference (range) (compared with screening) 730 (109e4383) 17 ( 8e218), n¼9
p Value* 0.007 0.17
High
Median (range) 3 (0e14) 1730 (758e2138) 42 (33e256)
Median difference (range) (compared with screening) 1721 (743e2135) 42 (27e247)
p Value* 0.005 0.007
Single pooled peptidesdwithin-dose changes from screening to peak and plateau
Low
Median (range) 0 (0e8), n¼9 393 (67e1275), n¼91 3 ( 2 e103), n¼9
Median difference (range) (compared with screening) 393 (60e1272), n¼91 3 ( 2 e97), n¼9
p Value* 0.009 0.032
High
Median (range) 0 (0e8) 502 (312e677) 14 (0e68)
Median difference (range) (compared with screening) 502 (294e677) 14 (0e66)
p Value* 0.005 0.048
*Wilcoxon signed rank test.
Table 5 Ex vivo IFN-g ELISpot statistics (2): comparison of responses between HIV-infected and HIV-uninfected subjects, at
each time-point and each vaccine dose, using ManneWhitney U test
Summed
pooled
peptides
Median
(range) HIV+
Median
(range) HIVL
Difference in
medians (95% CI) p Value*
HIV-infected versus HIV-negative group
Week 1 Low dose 738 (109e4398),
n¼10
2147 (1173e5085),
n¼21
1101 ( 393 to 2873) 0.12
High dose 1730 (758e2138),
n¼10
6493 (4854e7312),
n¼12
4557 (3038 to 5904) 0.0001
Week 24 Low dose 20 (0e237),
n¼9
385 (228e1010),
n¼20
339 (161 to 534) 0.004
High dose 42 (33e256),
n¼10
970 (655e1199),
n¼12
820 (569 to 1050) 0.0001
Area under
the curve
Low dose 2162 (519e23348),
n¼9
16317 (9129e36418),
n¼20
11884 (3191 to 17387) 0.02
High dose 5929 (3167e11607),
n¼10
41575 (26919e53807),
n¼12
31384 (20778 to 45504) 0.0001
*Mann Whitney U test.
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Phase I study with MVA85A in HIV(Scriba et al, submitted) and Senegal (Mboup et al,
unpublished data) are ongoing.
The local and systemic AE proﬁles in this trial were
comparable with those observed in HIV-uninfected
subjects previously. While we have not evaluated the
safety of this vaccine in HIV-infected subjects with lower
CD4 counts, we would not expect the safety proﬁle of
this vaccine to be altered by progression of HIV disease.
Importantly, there were no clinically signiﬁcant effects of
vaccination on either CD4 count or HIV RNA load. It is
important to understand the variability in these param-
eters during stable untreated HIV infection, to enable
meaningful interpretation of ﬂuctuations throughout
the trial period. A recent quantitative review of cohort
studies of HIV-infected adults suggests that, during
stable untreated infection, intraindividual HIV RNA
measurements can ﬂuctuate over short periods of time
by as much as 0.2e0.5 log10 copies/ml, with measure-
ment error and physiological ﬂuctuation each contrib-
uting about 50% of this variation. CD4 counts can also
vary within patients by 60e130 cells/ml within weeks, but
there is less measurement error, and during stable
infection the overall within-subject variation is propor-
tionally larger for HIV RNA than for the CD4 count.
23 In
this study, we also observed greater intraindividual vari-
ations in HIV RNA load compared with CD4 counts.
Only one subject in each group demonstrated a more
than 0.5 log rise in HIV RNA load at week 24 post-
vaccination. The ﬁrst of these (low-dose group, 008) had
displayed a relatively high baseline HIV RNA load and
low baseline CD4 count at screening, just within the
inclusion criteria. As the rise in HIV RNA load was only
detectable 24 weeks after vaccination, it was considered
highly unlikely that this was due to MVA85A vaccination.
This subject commenced ARVs before week 24; all other
subjects remained ARV-free throughout the trial period.
The second subject (high-dose group, 035) developed
a rise in HIV RNA load between week 12 and week 24,
peaking at just greater than a 0.5 log increase over
baseline. However, this subject’s HIV RNA load had been
stable prior to this, so it was again deemed unlikely that
this was a vaccination-related effect. Other ﬂuctuations
in the HIV RNA loads were observed, but any sustained
rise was well within the expected 0.5 log variation.
Figure 3 Ag85A-speciﬁc
cytokine/chemokine production by
CD4 T cells pre and post
vaccination. MVA85A induces
polyfunctional Ag85A-speciﬁc CD4
T cells in HIV-infected individuals.
MVA85A vaccination-induced
production of IFN-g, IL-2, MIP-1b
and TNF-a by antigen-speciﬁc
CD4 T cells was assessed
following Ag85A peptide
stimulation of cryopreserved
PBMC using polychromatic ﬂow
cytometry. (A) Individual data
points shown with a median line,
IQR (open bars) and range
(whiskers) at baseline and at each
time-point postvaccination for
every possible combination of
cytokine/chemokine production.
High-dose and low-dose groups
were analysed together (n¼17).
(B) Functional proﬁle of the Ag85A-
speciﬁc CD4 T cell response
summarised in pie charts (n¼17).
CD4 T cells producing a given
number of cytokines/chemokines
are grouped and colour-coded
together. Pie charts are shown for
the high-dose HIV-infected group
(n¼9), low-dose HIV-infected
group (n¼8) and low-dose healthy
controls (n¼6). (C) Absolute
percentages of the highest
frequency CD4 T cell subsets
producing speciﬁc combinations of
chemokine/cytokines at week 1
postvaccination across the different
groups; *p<0.05, **p<0.01.
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24 25 in
particular HIV-speciﬁc memory CD4 T cells,
20 and other
activated antigen-speciﬁc CD4 Tcells.
26 Using a sensitive
qPCR method, we detected HIV gag DNA in Ag85A-
speciﬁc CD4 T cells from only 1/11 subjects post-
vaccination (three low-dose and eight high-dose). This
subject received high-dose MVA85A vaccination. This
low positivity rate concurs with the stable CD4 count and
HIV RNA load parameters in most subjects throughout
the trial. Although the qPCR assay is sensitive, the low
yield of Ag85A-speciﬁc CD4 Tcells entering the assay is an
important limitation and provides just a snapshot of the
HIV burden within the Ag85A-speciﬁc CD4 T cell pool,
and warrants further future investigation. However, while
small effects of MVA85A on HIV infection of CD4 target
cells cannot be excluded given the small sample size,
these data suggest that MVA85A vaccination of healthy
HIV-infected individuals does not lead to widespread
preferential infection and depletion of vaccine-induced
CD4 T cell populations in the periphery. These data are
supported by no change in surface expression of the HIV
co-receptor CCR5 following MVA85A vaccination. In
addition, the lack of effect of vaccination on chemokine
and cytokine levels in unstimulated serum supports the
interpretation that vaccination with MVA85A did not lead
to widespread immune activation in this subject group.
We have shown that vaccine-induced immunogenicity,
while of moderate magnitude, is signiﬁcantly lower than
in healthy HIV-uninfected subjects given the same dose
of MVA85A. Thus, additional strategies may be required
to augment immune responses to MVA85A vaccination
in the context of HIV infection. Partial reconstitution of
the immune system with ARVs may improve the response
to vaccination. Indeed, this study shows that the baseline
HIV RNA level is a strong negative predictor of summed
85A peptide pool responses at week 24 postvaccination.
In addition, a booster vaccination with MVA85A may be
required to enhance the vaccine-induced immune
response.
The functional proﬁle of Ag85A-speciﬁc CD4 T cells
observed in this study was remarkably comparable with
that of healthy HIV-uninfected subjects
19 and M tuber-
culosis-infected subjects,
10 although the response in HIV-
infected subjects is less durable. IFN-g and TNF-a are
known to be important for protective immunity to TB,
and these cytokines dominated the MVA85A vaccine-
induced CD4 Tcell response elicited in the current study
cohort. In this study, production of MIP-1b by Ag85A-
speciﬁc CD4 T cells was not detectable after week 2
postvaccination. The production of multiple cytokines
including IL-2 and MIP-1b by HIV-speciﬁc CD8 T cells is
associated with long-term non-progression, albeit with
uncertain causality.
27 The production of b-chemokines
by CD8 T cells was not assessed here, as there were no
detectable Ag-85A speciﬁc CD8 T cell responses pre- or
postvaccination.
Vaccine-induced bystander activation of CD4 T cells in
HIV-infected subjects is likely to be undesirable because
activated CD4 T cells are at increased risk of HIV infec-
tion. The overall pattern of cytokine production and the
frequency of CMV-speciﬁc CD4 T cell producing cyto-
kines remained both relatively stable over the 24-week
period following MVA85A vaccination and comparable
with prevaccination responses (supplemental ﬁgure 1).
These data suggest that MVA85A vaccination does not
induce substantial bystander activation of antigen-
speciﬁc CD4 T cell populations.
AB
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Figure 4 Cytokine/chemokine production and receptor
expression. (A) Absolute percentage of Ag85A-speciﬁc CD4 T
cells producing IL-2 or MIP-1b at week 1 post-MVA85A
vaccination in HIV-infected subjects (low-dose and high-dose,
n¼17) versus healthy controls (n¼6). (B) Representative
histogram and (C) scatter plot showing CCR5 median
ﬂuorescence intensity (MFI) in naı ¨ve CD4 T cells, memory CD4
T cells and activated Ag85A-speciﬁc CD4 T cells at week 1 post
vaccination (n¼16 in all groups). (D) Scatter plot showing CCR5
integrated MFI (iMFI) for naı ¨ve, memory and Ag85A-speciﬁc
CD4 T cells (n¼16). Line charts showing CCR5 MFI in memory
CD4 T cells (E) and the total CD4 T cell population (F) across the
MVA85A vaccination time course (n¼16). *p<0.05, **p<0.01.
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Phase I study with MVA85A in HIVDemonstrating the safety and immunogenicity of
a new TB vaccine in an important target population is
a crucial step but does not mean that the vaccine will be
effective. However, the data presented here support
further safety and immunogenicity studies of this
candidate vaccine, together with proof-of-concept
efﬁcacy trials, in TB and HIV endemic areas.
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